Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 5
Balancing Survival and Quality of Life in 1L EGFRm NSCLC Treatment Decisions
Panelists discuss how treatment choice involves weighing quality of life against treatment burden, considering factors such as hospital visits for infusions vs oral medications at home.
Quality of Life vs Treatment Burden
Main Discussion Topics:
- Impact of different treatment regimens on patient quality of life
- Comparison of treatment burdens: oral therapy vs infusion-based regimens
- Consideration of financial costs and logistical challenges associated with different treatments
Key Points for Physicians:
- Treatment burden varies significantly: osimertinib is a daily pill with visits every 3 months, whereas combination therapies require infusions every 2 to 3 weeks
- More-intensive regimens involve greater “medicalization” of patient care
- Financial and logistical costs (travel, parking, childcare) must be considered
Notable Insights:
Patients fall on different ends of the spectrum regarding treatment preferences—some prioritize efficacy regardless of burden, and others prefer less- intensive regimens to maintain quality of life.
Clinical Significance:
The treatment decision ultimately depends on aligning therapy choice with individual patient values, circumstances, and priorities related to efficacy, quality of life, and treatment burden.
Related Content:
